Newsroom | 4896 results

MONTREAL--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Québec government for its recent decision to expand coverage of Dexcom Continuous Glucose Monitoring (CGM) Systems under the Régie de l’assurance maladie du Québec (RAMQ) for eligible Québecers aged 18 and older living with type 2 diabetes who are treated with intensive insulin therapy (IIT)*. According to Diabète Québec, type 2 diabetes is the most common form, affecting nearly 90% of th...

LOS ANGELES--(BUSINESS WIRE)--City of Hope today announced that Dr. Christine M. Lovly will spearhead the development of its new national thoracic oncology program starting Jan. 1....

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2025 and reaffirmed full year 2025 guidance. Third Quarter 2025 and Recent Highlights Achieved record third quarter sales both in the United States (U.S.) and internationally Demonstrated year-over-year and sequential gross margin improvement Progressed multi-channel initiative by: Increasing ph...

FT. LAUDERDALE, Fla.--(BUSINESS WIRE)--Trividia Health, Inc., announced today that it’s TRUE METRIX® Self-Monitoring Blood Glucose Systems are now preferred for commercial patients on CVS Caremark Commercial Template Formularies in the United States, replacing OneTouch® branded blood glucose monitors and test strips. The TRUE METRIX® portfolio delivers scientifically backed performance built on decades of research and technological innovation. The TRUE METRIX meters and test strips feature TRIP...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA® (finerenone) significantly reduced urine albumin-to-creatinine ratio (UACR) from baseline over six months by 25% compared to placebo in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) who were receiving standard of care (95% CI=0.75 [0.65; 0.87]; p=0.0001).1 These late-breaking data were presented today at the opening plenary sessi...

MONTRÉAL--(BUSINESS WIRE)--La RAMQ permet désormais aux résidents du Québec admissibles d’avoir accès au système de surveillance continue du glucose (SCG) Dexcom....

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended September 30, 2025. Financial Results “The third quarter marked another period of robust growth in our hypercortisolism business. Once again, we had...

SAN FRANCISCO & ATLANTA--(BUSINESS WIRE)--Aion Medicines, a subsidiary of Exavir Therapeutics, announced the presentation of preclinical data for AM-710, the company’s ultra-long-acting small molecule GLP1R agonist, at the ObesityWeek conference in Atlanta, GA demonstrating the potential for a best-in-class profile and multi-month dosing intervals. “These impressive data demonstrate that AM-710 is a unique and highly differentiated compound in a complex and evolving landscape,” said Tim Garnett...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it achieved ISO/IEC 27001:2022 Certification from Insight Assurance, affirming Tandem’s company-wide commitment to cybersecurity, data protection, and operational integrity. As Tandem continues to expand internationally, the ISO/IEC 27001:2022 certification strengthens its position in regulated markets and simplifies compliance for partners and healt...

MENLO PARK, Calif.--(BUSINESS WIRE)--OrsoBio will present clinical and preclinical data on its mitochondrial protonophore portfolio for obesity at ObesityWeek 2025....